Evidence map›Paper›PMID 35430687›Full record

ReviewJournal of cancer research and clinical oncology2022

Management of secondary Paget's disease of the vulva associated with transitional cell carcinoma.

S Kajtezovic, Allison R Walker, B Hjalmarsson, S G Bell, E Everett, C Wong

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

S KajtezovicThe University of Vermont Larner College of Medicine, Burlington, VT, USA.
Allison R WalkerDepartment of Obstetrics and Gynecology, University of Vermont Medical Center, 111 Colchester Ave, Mail code: 251 Smith 4, Burlington, VT, 05401, USA. walkerallison86@gmail.com.ORCID http://orcid.org/0000-0001-6865-2556
B HjalmarssonDepartment of Obstetrics and Gynecology, University of Vermont Medical Center, 111 Colchester Ave, Mail code: 251 Smith 4, Burlington, VT, 05401, USA.
S G BellDepartment of Obstetrics and Gynecology, University of Vermont Medical Center, 111 Colchester Ave, Mail code: 251 Smith 4, Burlington, VT, 05401, USA.
E EverettDepartment of Gynecologic Oncology, University of Vermont Medical Center, Burlington, VT, USA.
C WongDepartment of Gynecologic Oncology, University of Vermont Medical Center, Burlington, VT, USA.
University of Vermont Medical Center · USUniversity of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSecondary extramammary Paget's disease (EMPD) related to urothelial carcinoma is rare, with some cases presenting synchronously with either a primary neoplasm or recurrence of a neoplasm and other cases presenting up to 13 years prior to the detection of urothelial carcinoma. In this report, we will review the presentation, diagnosis, pathophysiology, management, and literature review of cases of secondary EPMD associated with urothelial carcinoma.

methodsWe reviewed the English literature for all cases of secondary EMPD presenting synchronously with or in patients with a history of urothelial carcinoma, as well as treatment data for secondary vulvar Paget's.

resultsWe identified 16 case reports and case series with a total of 20 cases of vulvar EMPD associated with urothelial carcinoma. Twelve cases presented asynchronously and 8 had EMPD preceding the diagnosis of the underlying neoplasm. There is a paucity in the literature regarding management and surgical resection is a common treatment strategy; however, nonsurgical interventions may also be effective.

conclusionThere is a paucity in the literature regarding management of secondary EPMD of urothelial origin, but consideration of radiation and systemic chemotherapy may be a reasonable treatment approach.

Indexed as

Carcinoma, Transitional CellPaget Disease, ExtramammaryUrinary Bladder NeoplasmsVulvar NeoplasmsFemaleHumansVulvaImmunohistochemistrySecondary vulvar Paget’s diseaseTransitional cell carcinomaUrothelial carcinomaVulvar Paget’s disease

Identifiers

PMID35430687
PMCPMC11800952
OpenAlexW4224134992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.